Company intelligence / Profile preview
Mebiopharm
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
Overview
Mebiopharm develops novel anticancer drugs using proprietary liposome-based drug delivery systems. Their lead assets include a transferrin-targeted, methotrexate-loaded liposomal product licensed to Fuan Pharmaceutical for China, a Nek2 siRNA nucleic acid drug under academic collaboration with Nagoya University, and nanoparticle ultrasound contrast agents. The company has ongoing partnerships with major pharma companies like Merck and academic institutions such as Osaka University. At least one program has reached Phase 2 trials in Europe; others are at various stages from preclinical to early clinical development.
- Therapeutic areas
- Oncology
- Modalities
- Liposome-based drug delivery therapyNucleic acid (siRNA) therapySmall moleculeNanoparticle-based contrast agent
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Mebiopharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mebiopharm.